In the news
See all news
July 27, 2017
Following the direction set last year when GCT established clinical operations in three new countries – Hungary, Czech Republic, and Slovakia, – in May 2017 the company moved further into Central Europe and opened an office in Warsaw, Poland. GCT presently offers its clients full assistance for clinical trials conduct in Poland, including feasibility studies, clinical monitoring, study management, and regulatory support.
July 26, 2017
GCT team in Budapest has started trainings for the newest ophthalmic project which we were recently awarded by our long-term partners. The study is an EU multinational Phase II clinical trial involving patients with diabetic macular edema.
We are delighted to demonstrate our expertise in clinical research within eye diseases field yet again. Our previous experience includes such indications as subfoveal choroidal neovascularization in subjects with pathologic myopia, diabetic retinopathy, age-related macular degeneration, open-angle glaucoma, ocular hypertension, dry eye symptoms after refractive surgery, and others.
July 14, 2017
Inventive device, designed to provide permanent relief of the obstructions in patients with prostatic enlargement, will be tested in Slovakia. GCT is eager to apply and deepen our expertise in managing Urology and Medical Devices clinical trials in EU.
Benign prostatic hyperplasia (BPH) is a common condition in men 50 years and older that can be clinically observed as lower-urinary tract symptoms. There are several treatment options that include pharmacotherapy, minimally invasive therapies and surgery. The gold standard for surgical intervention has been transurethral resection of the prostate (TURP), but in recent years, as technology emerges, men tend to choose those less invasive options with fewer side-effects and morbidity. The new investigative prostate retraction device is intended to reduce most of the known side effects and complications caused by the usage of urethral stents.